CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
82.33
-0.25 (-0.30%)
As of 12:45PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close82.58
Open82.12
Bid82.17 x 4000
Ask82.22 x 800
Day's Range81.35 - 82.63
52 Week Range74.13 - 139.72
Volume1,304,584
Avg. Volume4,736,781
Market Cap57.908B
Beta (3Y Monthly)1.33
PE Ratio (TTM)22.89
EPS (TTM)3.60
Earnings DateOct 25, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est111.65
Trade prices are not sourced from all markets
  • 5 Stocks to Absolutely Love During This Correction
    Motley Fool3 days ago

    5 Stocks to Absolutely Love During This Correction

    The stock market is dropping, which means it could be time to go shopping.

  • Here's Why bluebird bio Dropped 13.3% in September
    Motley Fool4 days ago

    Here's Why bluebird bio Dropped 13.3% in September

    The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.

  • Analyzing Celgene’s Immunology and Inflammation Business
    Market Realist4 days ago

    Analyzing Celgene’s Immunology and Inflammation Business

    How's Celgene Positioned before Its Third-Quarter Earnings? Otezla’s net revenues grew from $358.0 million in the second quarter of 2017 to $375.0 million in the second quarter, which reflects ~4.7% growth YoY (year-over-year). In the US market, Otezla fell 4.9% YoY in the second quarter and reported revenues of $291.0 million.

  • Business Wire4 days ago

    Survey Results Presented at ECTRIMS Reveal People with Multiple Sclerosis Want More Information on Brain Atrophy

    A new survey examines the topic of brain volume loss, known as brain atrophy, in people with multiple sclerosis. The survey findings, presented at ECTRIMS 2018, suggest that there is a high level of interest in better understanding how brain atrophy may impact disease progression. The survey, conducted by the Multiple Sclerosis Association of America (MSAA) and sponsored by Celgene, included more than 1,300 people with multiple sclerosis or someone responding on their behalf.

  • Investopedia5 days ago

    Top 3 Healthcare Stocks for 2018

    The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.

  • Celgene: Multiple Myeloma Franchise Could Drive Growth
    Market Realist5 days ago

    Celgene: Multiple Myeloma Franchise Could Drive Growth

    How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).

  • Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
    Zacks5 days ago

    Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status

    Data presentations by leading sector players take center stage this week.

  • Celgene: Analysts’ Views before Its Third-Quarter Earnings
    Market Realist5 days ago

    Celgene: Analysts’ Views before Its Third-Quarter Earnings

    Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.

  • Reuters5 days ago

    BRIEF-Beigene Announces National Reimbursement Inclusion Of Vidaza® (Azacitidine For Injection) By The State Medical Insurance Administration In China

    Oct 10 (Reuters) - Beigene Ltd: * BEIGENE ANNOUNCES NATIONAL REIMBURSEMENT INCLUSION OF VIDAZA® (AZACITIDINE FOR INJECTION) BY THE STATE MEDICAL INSURANCE ADMINISTRATION IN CHINA * BEIGENE SAYS VIDAZA ...

  • Business Wire5 days ago

    New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018

    Ozanimod showed effects on cognitive processing speed in a post hoc analysis of 12-month data from SUNBEAM™ pivotal trial

  • The Wall Street Journal6 days ago

    [$$] The Menendez Method

    After narrowly dodging a corruption conviction, New Jersey Senator Bob Menendez faces a re-election dogfight against former Celgene CEO Bob Hugin. The Senator is now lying to voters about his opponent’s business record the way he dissembled about his political corruption. Democrats always treat a Republican candidate from business as if commerce is by definition criminal, and Mr. Hugin is no exception.

  • Better Buy: Crispr Therapeutics AG vs. Editas
    Motley Fool6 days ago

    Better Buy: Crispr Therapeutics AG vs. Editas

    Which gene editing start-up has the best chance to outperform in the years ahead?

  • A Financial Overview of Neurocrine Biosciences in October
    Market Realist6 days ago

    A Financial Overview of Neurocrine Biosciences in October

    Neurocrine Biosciences’ (NBIX) revenues grew from $6.3 million in the second quarter of 2017 to $96.9 million in the second quarter. The company reported net revenues of $168.0 million in the first half of this year, which grew from $6.3 million in the first half of 2017. Wall Street analysts expect Neurocrine Biosciences to generate revenues of $151.8 million in the third quarter.

  • Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study
    Zacks6 days ago

    Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study

    Celgene's (CELG) efforts to expand psoriasis drug, Otezla gets a boost as the late-stage study for the indication of plaque psoriasis of the scalp meets primary endpoint.

  • Benzinga6 days ago

    The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 8) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...

  • Business Wire7 days ago

    Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint

    Celgene Corporation (CELG) today announced results from the phase 3 STYLE study, which showed that OTEZLA® (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment (ScPGA) response [defined as ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline] at week 16 compared with placebo. In addition to achieving the primary endpoint, statistical significance was also met for the secondary endpoint of the whole body itch numeric rating scale (NRS) [defined as at least a 4-point reduction from baseline] at week 16 with OTEZLA versus placebo. The safety profile was generally consistent with the known safety profile of OTEZLA, and no new safety signals were identified in the trial.

  • See what the IHS Markit Score report has to say about Celgene Corp.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Celgene Corp.

    Celgene Corp NASDAQ/NGS:CELG

  • Celgene (CELG) Dips More Than Broader Markets: What You Should Know
    Zacks10 days ago

    Celgene (CELG) Dips More Than Broader Markets: What You Should Know

    Celgene (CELG) closed at $87.27 in the latest trading session, marking a -1.47% move from the prior day.

  • Cara Therapeutics: Performance and Estimates for Q3
    Market Realist10 days ago

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics (CARA) is a clinical-stage biotechnology company that develops new chemical entities for managing pain and pruritus. It reported EPS of -$0.52 on revenues of $2.87 million in the second quarter.

  • 3 Top Small-Cap Stocks to Buy Right Now
    Motley Fool11 days ago

    3 Top Small-Cap Stocks to Buy Right Now

    Sometimes great stocks come in small packages.

  • Ionis Pharmaceuticals’ Revenue Stream
    Market Realist11 days ago

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.

  • Investopedia12 days ago

    Top 5 Biotech Stocks for 2018

    Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Given Celgene's solid long-term track record, the lackluster year-to-date performance may represent a buying opportunity.

  • Cantor Fitzgerald Starts Coverage of Health Care Stocks
    GuruFocus.com13 days ago

    Cantor Fitzgerald Starts Coverage of Health Care Stocks

    Cantor Fitzgerald has initiated coverage of Celgene Corp. (CELG) with an overweight rating. The analyst established a price target of $100 per share, which represents an 11.3% upside from the share price of $89.88 at close Monday. Warning! GuruFocus has detected 3 Warning Signs with CELG.

  • 2 Stocks That Can Safely Double Your Money
    Motley Fool13 days ago

    2 Stocks That Can Safely Double Your Money

    AstraZeneca and Celgene Corporation are both outstanding buys for long-term-oriented investors. Here's why.

  • Business Wire14 days ago

    Celgene Corporation to Announce Third Quarter 2018 Results on October 25, 2018

    Celgene Corporation (CELG) will host a conference call and live audio webcast on Thursday, October 25, 2018 at 9 a.m. ET to discuss third quarter 2018 financial and operational results. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.